European mistletoe contains chemicals that might stimulate the immune system and kill certain cancer cells, but it's not clear if these effects occur in the human body.
People use European mistletoe for various types of cancer, including head and neck cancer, bladder cancer, breast cancer, lung cancer, and many other conditions, but there is no good scientific evidence to support these uses. Most research has evaluated European mistletoe injections given by a healthcare provider. There is very little research on the use of European mistletoe taken by mouth.
Uses & Effectiveness ?
Possibly Ineffective for
- Head and neck cancer. Injecting European mistletoe extract into the skin before or after surgery or radiation for head and neck cancers does not improve survival. It's not clear if taking European mistletoe by mouth helps. Injection products can only be given by a healthcare provider.
- The most serious type of skin cancer (melanoma). Injecting European mistletoe extract into the skin after surgery for melanoma does not improve survival or reduce the risk of the cancer returning. It's not clear if taking European mistletoe by mouth helps. Injection products can only be given by a healthcare provider.
Special Precautions and Warnings
Pregnancy: European mistletoe is likely unsafe when taken by mouth during pregnancy. It might stimulate the uterus and cause a miscarriage.
Breast-feeding: There isn't enough reliable information to know if European mistletoe is safe to use when breast-feeding. Stay on the safe side and avoid use.
"Auto-immune diseases" such as multiple sclerosis (MS), lupus (systemic lupus erythematosus, SLE), rheumatoid arthritis (RA), or other conditions: European mistletoe might cause the immune system to become more active. This could increase the symptoms of auto-immune diseases. If you have one of these conditions, it's best to avoid using European mistletoe.
Leukemia: European mistletoe might make leukemia worse. If you have leukemia, don't take European mistletoe.
Organ transplant: European mistletoe might make the immune system more active. A more active immune system might increase the risk of organ rejection. If you have had an organ transplant, avoid European mistletoe.
Surgery: European mistletoe might affect blood pressure. This might interfere with blood pressure control during and after surgery. Stop taking European mistletoe at least 2 weeks before a scheduled surgery.
Medications for high blood pressure (Antihypertensive drugs) interacts with EUROPEAN MISTLETOE
European mistletoe might lower blood pressure. Taking European mistletoe along with medications that lower blood pressure might cause blood pressure to go too low. Monitor your blood pressure closely.
Medications that decrease the immune system (Immunosuppressants) interacts with EUROPEAN MISTLETOE
European mistletoe can increase the activity of the immune system. Some medications, such as those used after a transplant, decrease the activity of the immune system. Taking European mistletoe along with these medications might decrease the effects of these medications.
Be cautious with this combination
Baek JH, Jeon Y, Han KW, Jung DH, Kim KO. Effect of mistletoe extract on tumor response in neoadjuvant chemoradiotherapy for rectal cancer: a cohort study. World J Surg Oncol 2021;19(1):178. View abstract.
Bauer C, Oppel T, Rueff F, Przybilla B. Anaphylaxis to viscotoxins of mistletoe (Viscum album) extracts. Ann Allergy Asthma Immunol 2005;94:86-9. View abstract.
Böcher E, Stumpf C, Büssing A, and et al. [Prospective assessment of toxicity of high dose Viscum album L. infusions in patients with progressive malignomas]. Zeitschrift fur Onkologie 1996;28(4):97-106.
Büssing A, Raak C, Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Alternat Med. 2012;2012:219402. View abstract.
Bussing A, Regnery A, Schweizer K. Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett 1995;94:199-205.. View abstract.
Bussing A, Stumpf C, Troger W, Schietzel M. Course of mitogen-stimulated T lymphocytes in cancer patients treated with Viscum album extracts. Anticancer Res. 2007 Jul-Aug;27(4C):2903-10. View abstract.
Casetti F, Rafei-Shamsabadi D, Müller S. Grade II-anaphylaxis after subcutaneous injection of mistletoe extract. Contact Dermatitis 2021;85(4):462-5. View abstract.
Cazacu, M., Oniu, T., Lungoci, C., Mihailov, A., Cipak, A., Klinger, R., Weiss, T., and Zarkovic, N. The influence of isorel on the advanced colorectal cancer. Cancer Biother.Radiopharm. 2003;18(1):27-34. View abstract.
Chernyshov VP, Omelchenko LI, Heusser P, and et al. Immunomodulatory actions of Viscum album (Iscador) in children with recurrent respiratory disease as a result of the Chernobyl nuclear accident. Complementary Therapies in Medicine 1997;5(3):141-146.
Chernyshov, V. P., Heusser, P., Omelchenko, L. I., Chernyshova, L. I., Vodyanik, M. A., Vykhovanets, E. V., Galazyuk, L. V., Pochinok, T. V., Gaiday, N. V., Gumenyuk, M. E., Zelinsky, G. M., Schaefermeyer, H., and Schaefermeyer, G. Immunomodulatory and clinical effects of Viscum album (Iscador M and Iscador P) in children with recurrent respiratory infections as a result of the Chernobyl nuclear accident. Am J Ther. 2000;7(3):195-203. View abstract.
Cho SJ, Kim SW, Chang JW. Acute pneumonitis consequent on pleurodesis with Viscum album extract: severe chest images but benign clinical course. Multidiscip Respir Med. 2014 Nov 27;9(1):61. View abstract.
Deliorman D, Calis I, Ergun F. A new acyclic monoterpene glucoside from Viscum album ssp. album. Fitoterapia 2001;72:101-5.
Dold U, Edler L, Maurer HC, et al., eds. [Adjuvant Cancer Therapy in Advanced Non-Small Cell Bronchial Cancer: Multicentric Controlled Studies To Test the Efficacy of Iscador and Polyerga]. Stuttgart, Germany: Georg Thieme Verlag, 1991.
Douwes FR, Kalden M, Frank G, and et al. [Treatment of advanced colorectal carcinoma: efficacy test of the combination of 5-fluorouracil and tetrahydrofolic acid versus 5-fluorouracil and tetrahydrofolic acid in combination with an optimized Helixor treatment]. Deutsche Zeitschrift für Onkologie 1988;3:63-67.
Douwes, F. R., Wolfrum, D. I., and Migeod, F. [Results of a prospective randomized study on chemotherapy versus chemotherapy plus "biological response modifier" in metastatic colorectal carcinoma]. Krebsgeschehen 1986;18(6):155-164.
Elsasser-Beile U, Leiber C, Wolf P, et al. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract. J Urol 2005;174:76-9. View abstract.
Enesel, M. B., Acalovschi, I., Grosu, V., Sbarcea, A., Rusu, C., Dobre, A., Weiss, T., and Zarkovic, N. Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients. Anticancer Res 2005;25(6C):4583-4590. View abstract.
Ernst E, Schmidt K, Steuer-Vogt MK. Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 2003;107:262-7.. View abstract.
Evans M, Bryant S, Huntley AL, Feder G. Cancer Patients' Experiences of Using Mistletoe (Viscum album): A Qualitative Systematic Review and Synthesis. J Altern Complement Med. 2016 Feb;22(2):134-44. View abstract.
Finall AI, McIntosh SA, Thompson WD. Subcutaneous inflammation mimicking metastatic malignancy induced by injection of mistletoe extract. BMJ 2006;333:1293-4. View abstract.
Friess H, Beger HG, Kunz J, et al. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Anticancer Res 1996 Mar-Apr;16:915-20. View abstract.
Gorter, R. W., van Wely, M., Reif, M., and Stoss, M. Tolerability of an extract of European mistletoe among immunocompromised and healthy individuals. Altern.Ther.Health Med 1999;5(6):37-38. View abstract.
Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). Forsch Komplementarmed 2006;13:285-92. View abstract.
Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador. Arzneimittelforschung. 2007;57(10):665-78. View abstract.
Grossarth-Maticek, R. and Ziegler, R. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis. Eur J Med Res 11-30-2006;11(11):485-495. View abstract.
Grossarth-Maticek, R. and Ziegler, R. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). Eur.J Med Res 3-31-2008;13(3):107-120. View abstract.
Grossarth-Matichek R, Kiene H, Baumgartner SM, Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 2001;7:57-66, 68-72, 74-6 passim. View abstract.
Gutsch J. [On the state of therapy of chronic myeloid leukemia in adults with the mistletoe preparation Helixor]. Ärztezeitschrift für Naturheilverfahren Physikalische Medizin Und Rehabilitation 1982;23(9):523-544.
Harvey J, Colin-Jones DG. Mistletoe hepatitis. Br Med J (Clin Res Ed) 1981;282:186-7. View abstract.
Heiny BM. [Adjuvant treatment with standardized mistletoe extract reduces leukopenia and improves the quality of life of patients with advanced carcinoma of the breast getting palliative chemotherapy (VEC regimen)]. Krebsmedizin 1991;12:3-14.
Heinzerling L, von Baehr V, Liebenthal C, et al. Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo. J Clin Immunol 2006;26:347-59. View abstract.
Huber R, Barth H, Schmitt-Graff A, Klein R. Hypereosinophilia induced by high-dose intratumoral and peritumoral mistletoe application to a patient with pancreatic carcinoma. J Altern Complement Med 2000;6:305-10. View abstract.
Huber R, Klein R, Lüdtke R, Werner M. [Frequency of the common cold in healthy subjects during exposure to a lectin-rich and a lectin-poor mistletoe preparation in a randomized, double-blind, placebo-controlled study]. Forsch Komplementarmed Klass Naturheilkd. 2001 Dec;8(6):354-8. View abstract.
Huber R, Schlodder D, Effertz C, Rieger S, Troger W. Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer. BMC Complement Altern Med. 2017 Sep 18;17(1):465. View abstract.
Huber, R., Ludtke, R., Klassen, M., Muller-Buscher, G., Wolff-Vorbeck, G., and Scheer, R. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study. Eur.J Med Res 9-28-2001;6(9):399-405. View abstract.
Jung ML, Baudino S, Ribereau-Gayon G, et al. Characterization of cytotoxic proteins from mistletoe (Viscum album L.). Cancer Lett 1990;51:103-8.. View abstract.
Kaegi E. Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 1998;158:1157-9. View abstract.
Khan T, Ali S, Qayyum R, Hussain I, Wahid F, Shah AJ. Intestinal and vascular smooth muscle relaxant effect of Viscum album explains its medicinal use in hyperactive gut disorders and hypertension. BMC Complement Altern Med. 2016 Jul 27;16:251. View abstract.
Kienle GS, Grugel R, Kiene H. Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters. BMC Complement Altern Med. 2011 Aug 28;11:72. View abstract.
Kim HJ, Kim H, Ahn JH, Suk JH. Liver injury induced by herbal extracts containing mistletoe and kudzu. J Altern Complement Med 2015;21(3):180-5. View abstract.
Kim JD, Choi JW, Park HO, et al. Chemical pleurodesis with Viscum album L. extract for secondary spontaneous pneumothorax in elderly patients. J Thorac Dis 2020;12(10):5440-5445. View abstract.
Kim KC, Yook JH, Eisenbraun J, Kim BS, Huber R. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. BMC Complement Altern Med. 2012 Oct 3;12:172. View abstract.
Kim M, Park Y, Lee S, and et al. [Comparative study on the effects of a Viscum album (L.) extract (mistletoe) and doxycycline for pleurodesis in patients with malignant pleural effusion]. Korean Journal of Medicine 1999;57(suppl 2):s121.
Kirchberger, I., Wetzel, D., and Finger, T. Development and validation of an instrument to measure the effects of a mistletoe preparation on quality of life of cancer patients: the Life Quality Lectin-53 (LQL-53) Questionnaire. Qual.Life Res. 2004;13(2):463-479. View abstract.
Kleeberg, U. R., Suciu, S., Brocker, E. B., Ruiter, D. J., Chartier, C., Lienard, D., Marsden, J., Schadendorf, D., and Eggermont, A. M. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur.J Cancer 2004;40(3):390-402. View abstract.
Kuttan G, Kuttan R. Immunological mechanism of action of the tumor reducing peptide from mistletoe extract (NSC 635089) cellular proliferation. Cancer Lett 1992;66:123-30.. View abstract.
Kuttan G, Vasudevan DM, Kuttan R. Isolation and identification of a tumour reducing component from mistletoe extract (Iscador). Cancer Lett 1988;41:307-14.. View abstract.
Kuttan G, Vasudevan DM, Kuttan R. Presence of a receptor for the active component of Iscador in ascites fluid of tumour bearing mice. Cancer Lett 1989;48:223-7.. View abstract.
Lee YG, Jung I, Koo DH, et al. Efficacy and safety of Viscum album extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancer. Support Care Cancer 2019;27(5):1945-9. View abstract.
Loef M, Walach H. Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis. BMC Complement Med Ther 2020;20(1):227. View abstract.
Longhi A, Cesari M, Serra M, Mariani E. Long-Term Follow-up of a Randomized Study of Oral Etoposide versus Viscum album Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse. Sarcoma 2020;2020:8260730. View abstract.
Longhi A, Reif M, Mariani E, Ferrari S. A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients. Evid Based Complement Alternat Med. March 2014:210198. View abstract.
Natl Cancer Inst. Mistletoe (PDQ). CancerNet. www.cancernet.nci.nih.gov/cam/mistletoe.htm#7 (Accessed 30 March 2001).
Nazaruk J, Orlikowski P. Phytochemical profile and therapeutic potential of Viscum album L. Nat Prod Res. 2016;30(4):373-85. View abstract.
Noh D, Park JS, Lee DY. Acute respiratory distress syndrome after Viscum album pleurodesis for primary spontaneous pneumothorax. Koren J THorac Cariodvasc Surg. 2017 Feb;50(1):64-67. View abstract.
Olsnes S, Stirpe F, Sandvig K, Pihl A. Isolation and characterization of viscumin, a toxic lectin from Viscum album L. (mistletoe). J Biol Chem 1982;257:13263-70.. View abstract.
Pelzer F, Tröger W, Nat DR. Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study. J Altern Complement Med. 2018;24(9-10):954-961. View abstract.
Piao, B. K., Wang, Y. X., Xie, G. R., Mansmann, U., Matthes, H., Beuth, J., and Lin, H. S. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 2004;24(1):303-309. View abstract.
Salzer G, Danmayr E, Wutzlhofer F, and et al. [Adjuvant Iscador treatment of operated non small cell lung cancer]. Dtsch Zschr Onkol 1991;23(4):93-98.
Schad F, Atxner J, Buchwald D, Happe A, Popp S, Kröz M, Matthes H. Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis. Integr Cancer Ther. 2014 Jul;13(4):332-40. View abstract.
Schad F, Axtner J, Kroz M, Matthes H, Steele ML. Safety of combined treatment with monoclonal antibodies and Viscum album L preparations. Integr Cancer Ther. 2018 Mar;17(1):41-51. View abstract.
Schad F, Thronicke A, Steele ML, et al. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One. 2018;13(8):e0203058. View abstract.
Schaefermeyer G, Schaefermeyer H. Treatment of pancreatic cancer with Viscum album (Iscador): a retrospective study of 292 patients 1986-1996. Complement Ther Med 1998;6:172-7.
Schoffski P, Breidenbach I, Krauter J, et al. Weekly 24 h infusion of aviscumine (rViscumin): A phase I study in patients with solid tumours. Eur J Cancer 2005;41:1431-8. View abstract.
Semiglasov, V. F., Stepula, V. V., Dudov, A., Lehmacher, W., and Mengs, U. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res. 2004;24(2C):1293-1302. View abstract.
Semiglazov, V. F., Stepula, V. V., Dudov, A., Schnitker, J., and Mengs, U. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 2006;26(2B):1519-1529. View abstract.
Steele ML, Axtner J, Happe A, Kröz M, Matthes H, Schad F. Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients. Evid Based Complement Alternat Med. 2014;2014:724258. View abstract.
Steele ML, Axtner J, Happe A, Kröz M, Matthes H, Schad F. Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study. Evid Based Complement Alternat Med. 2014;2014:236310. View abstract.
Steele ML, Axtner J, Happe A, Kroz M, Matthes H, Schad F. Use and safety of intratumoral application of European mistletoe (Visum album L) preparations in oncology. Integr Cancer Ther. 2015 Mar;14(2):140-8. View abstract.
Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 2001;37:23-31.. View abstract.
Stirpe F, Sandvig K, Olsnes S, et al. Action of viscumin, a toxic lectin from mistletoe, on cells in culture. J Biol Chem 1982;257:13271-7.. View abstract.
Styczynski J, Wysocki M. Alternative medicine remedies might stimulate viability of leukemic cells. Pediatr Blood Cancer 2006;46:94-8. View abstract.
Thronicke A, Matthes B, von Trott P, Schad F, Grah C. Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On Viscum album L: A Multicenter Real-World Study. Integr Cancer Ther 2020;19:1534735420940384. View abstract.
Thronicke A, Steele ML, Grah C, Matthes B, Schad F. Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. BMC Complement Altern Med. 2017 Dec 13;17(1):534. View abstract.
Timoshenko AV, Cherenkevich SN, Gabius HJ. Viscum album agglutinin-induced aggregation of blood cells and the lectin effects on neutrophil function. Biomed Pharmacother 1995;49:153-8.. View abstract.
Tröger W, Galun D, Reif M, Schumann A, Stankovic N, Milicevic M. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer. 2013 Dec;49(18):3788-97. View abstract.
Tusenius KJ, Spoek JM, Kramers CW. Iscador Qu for chronic hepatitis C: an exploratory study. Complement Ther Med 2001;9:12-6.. View abstract.
von Schoen-Angerer T, Wilkens J, Kienle GS, Kiene H, Vagedes J. High-Dose Viscum album Extract Treatment in the Prevention of Recurrent Bladder Cancer: A Retrospective Case Series. Perm J. 2015 Fall;19(4):76-83. View abstract.
Weissenstein U, Kunz M, Urech K, Regueiro U, Baumgartner S. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro. BMC Complement Altern Med. 2016 Aug 4;16:271. View abstract.
Zuzak TJ, Wasmuth A, Bernitzki S, Schwermer M, Längler A. Safety of high-dose intravenous mistletoe therapy in pediatric cancer patients: A case series. Complement Ther Med. 2018;40:198-202. View abstract.
Select a condition to view a list of vitamins
You Might Also Like
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2020.